- Eli Lilly (LLY, Financial) takes legal measures against telehealth companies for selling unauthorized versions of its drug, Mounjaro.
- Analysts forecast a potential upside for Eli Lilly, with an average price target of $1,016.05.
- GuruFocus estimates a significant upside in LLY's future GF Value, suggesting long-term growth potential.
Eli Lilly (LLY) has embarked on a legal challenge against four telehealth companies, alleging the sale of unauthorized and potentially unsafe compounded versions of its diabetes drug, tirzepatide, marketed as Mounjaro, and Zepbound for obesity. These compounded drugs, mixed with other substances, have not received FDA approval and lack essential clinical testing, thereby posing significant health risks to patients.
Wall Street Analysts Forecast
According to projections provided by 25 analysts, the one-year average price target for Eli Lilly and Co (LLY, Financial) stands at $1,016.05, with a high forecast of $1,190.00 and a low estimate of $800.00. These targets suggest a promising upside of 22.96% from the current trading price of $826.34. For a comprehensive view of these estimates, visit the Eli Lilly and Co (LLY) Forecast page.
The collective recommendation from 29 brokerage firms positions Eli Lilly and Co (LLY, Financial) with an average brokerage recommendation of 1.9, indicating an "Outperform" rating. This rating is part of a scale where 1 represents a Strong Buy, and 5 indicates a Sell.
GF Value Projection
According to projections by GuruFocus, the estimated GF Value for Eli Lilly and Co (LLY, Financial) in the coming year is pegged at $1125.03, indicating a potential upside of 36.15% from the current price of $826.34. The GF Value represents GuruFocus' assessment of the stock's fair trading value, calculated based on historical trading multiples, past business growth, and future performance estimates. For more in-depth data, please refer to the Eli Lilly and Co (LLY) Summary page.
